DSGN Design Therapeutics, Inc.
company
SEC Filings & Insider Trading Activity 2026

CIK: 1807120
Health Care
Pharmaceutical Preparations 24 filings
Russell 2000

Latest Design Therapeutics, Inc. (DSGN) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 28, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Design Therapeutics, Inc. (DSGN) (SEC CIK 1807120), with AI-powered section-by-section summaries updated daily.

10-Q: 15
10-K: 5
8-K: 4

Latest 2026 SEC Filing Dates

10-K Annual Report
Mar 9, 2026
10-Q Quarterly Report
Nov 5, 2025
8-K Current Report
Apr 28, 2026

AI 8-K Current Report Analysis
Recent 8-K Filings

Filed Mar 9, 2026
8-K
Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q4 and full-year 2025 earnings released March 9, 2026 — full figures in Exhibit 99.1
  • Filing furnished (not "filed"), limiting legal liability under Exchange Act Section 18

Recent 8-K Filings
Current Reports

AI-powered analysis of Design Therapeutics, Inc. (DSGN) 8-K current reports disclosing material events.

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Apr 28, 2026
8-K
Apr 1, 2026
10-K
Mar 9, 2026Dec 31, 2025
8-K
Mar 9, 2026Analysis
8-K
Jan 30, 2026
10-Q
Nov 5, 2025Sep 30, 2025
10-Q
Aug 7, 2025Jun 30, 2025
10-Q
May 7, 2025Mar 31, 2025
10-K
Mar 10, 2025Dec 31, 2024
10-Q
Nov 7, 2024Sep 30, 2024
10-Q
Aug 5, 2024Jun 30, 2024
10-Q
May 8, 2024Mar 31, 2024
10-K
Mar 19, 2024Dec 31, 2023
10-Q
Nov 13, 2023Sep 30, 2023
10-Q
Aug 14, 2023Jun 30, 2023
10-Q
May 9, 2023Mar 31, 2023
10-K
Mar 14, 2023Dec 31, 2022
10-Q
Nov 3, 2022Sep 30, 2022
10-Q
Aug 8, 2022Jun 30, 2022
10-Q
May 9, 2022Mar 31, 2022
10-K
Mar 10, 2022Dec 31, 2021
10-Q
Nov 9, 2021Sep 30, 2021
10-Q
Aug 9, 2021Jun 30, 2021
10-Q
May 10, 2021Mar 31, 2021

Frequently Asked Questions

What are the latest DSGN SEC filings in 2026?

Design Therapeutics, Inc. (DSGN) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did DSGN file its most recent 10-K annual report?

Design Therapeutics, Inc. (DSGN) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view DSGN 10-Q quarterly reports?

Design Therapeutics, Inc. (DSGN)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every DSGN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has DSGN filed recently?

Design Therapeutics, Inc. (DSGN)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find DSGN insider trading activity (Form 4)?

SignalX aggregates every DSGN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does DSGN file with the SEC?

Design Therapeutics, Inc. (DSGN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DSGN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Design Therapeutics, Inc. (DSGN).

What is DSGN's SEC CIK number?

Design Therapeutics, Inc. (DSGN)'s SEC CIK (Central Index Key) number is 1807120. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1807120 to look up all DSGN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find DSGN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Design Therapeutics, Inc. (DSGN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of Design Therapeutics, Inc. SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 24+ filings.